Taysha Gene Therapies, Inc.
2280 Inwood Road
Dallas, TX 75235
September 21, 2020 | VIA EDGAR |
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
| Attn: | Li Xiao |
Angela Connell |
Alan Campbell |
Suzanne Hayes |
| RE: | Taysha Gene Therapies, Inc. |
Registration Statement on Form S-1 |
File No. 333-248559 |
Acceleration Request
| Requested Date: | September 23, 2020 |
| Requested Time: | 4:00 P.M. Eastern Time |
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-1 (the “Registration Statement”) to become effective on September 23, 2020, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable.
Once the Registration Statement has been declared effective, please orally confirm that event with Madison Jones, counsel to the Registrant, at (202) 728-7087.
Very truly yours,
| Taysha Gene Therapies, Inc. | ||
/s/ RA Session II | ||
| RA Session II | ||
| President and Chief Executive Officer | ||
| cc: | Divakar Gupta, Cooley LLP |
Madison Jones, Cooley LLP |
